BERGENBIO TO PRESENT CLINICAL TRANSLATIONAL DATA FROM THE ONGOING PHASE II BEMCENTINIB COMBINATION STUDY IN NSCLC AT ANNUAL SITC MEETING
Bergen, Norway, 15 October 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that it has been selected for an oral presentation at the Society for Immunotherapy of Cancer (SITC) 35[th] Annual Meeting, taking place online from 9-14 November 2020. Abstract titles have been announced online here . BerGenBio will present clinical translational research updates from its Phase II